Form D · Biotechnology
Grannus Therapeutics, Inc.
Indianapolis, IN · CIK 0001905806
Offering snapshot reported Jan 12, 2024 · SEC filing
- Reported sold
- $800K Offering amount: $800K
- Investors reported
- 9 Form D · investor count
- Minimum accepted
- $250K Reported outside-investor minimum
- First sale
- Nov 17, 2023 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jan 12, 2024 | Initial | $800,000 | No comparison | 9 | SEC filing |
| Jan 21, 2022 | Initial | $950,000 | No comparison | 11 | SEC filing |
Offering details
- Securities
- Debt
- Exemptions
- 06b
- Duration over one year
- Yes
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-502310
Source: Form D, filed Jan 12, 2024. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Brian Blagg | Director |
| John Foglesong | Director, Executive |
| James Thompson | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
7210 N. Pennsylvania Street
Indianapolis, IN, 46240
Indianapolis, IN, 46240